-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Golimumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GP-531 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GP-531 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GP-531 in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baricitinib in Systemic-Onset Juvenile Idiopathic Arthritis (Still...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baricitinib in Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baricitinib in Juvenile Arthritis Drug Details: Baricitinib (Olumiant) is an anti-inflammatory,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Erosive Oral Lichen Planus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baricitinib in Erosive Oral Lichen Planus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baricitinib in Erosive Oral Lichen Planus Drug Details: Baricitinib...
-
Company Insights
NewAroCell AB Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our AroCell AB Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. AroCell AB (AroCell), formerly Xi Bao Research AB, is a vitro diagnostics company. It develops and commercializes tests used for the prognosis and monitoring of treatment of cancer. AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The company develops TK 210 ELISA kits for measuring the enzyme TK1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...